Allergan acquires regenerative medicine company LifeCell
Executive Summary
Allergan PLC acquired Acelity LP Inc.'s LifeCell Corp. business (regenerative medicine) for $2.9bn in cash in one of the largest device M&A deals of 2016. The transaction is expected to add $450mm in 2016 projected revenues with 75% gross margin and 40% operating margin.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Biomaterials
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice